Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR2 | Q969V1 | 2/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4245976 | 0.87 | DRD2 (0.58) | CHRM4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4246862 | 0.85 | ALDH1A1 (0.50) | HPGD | |
| SCHEMBL4240858 | 0.83 | HDAC1 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4189224 | 0.81 | GRIN2B (0.48) | — | |
| SCHEMBL4250549 | 0.78 | FAAH (0.50) | BCHE | |
| SCHEMBL4242462 | 0.76 | DRD2 (0.43) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4249819 | 0.76 | S1PR5 (0.44) | CHRM4LTA4H | |
| SCHEMBL4237299 | 0.76 | CHRNB2 (0.54) | CHRM4 | |
| SCHEMBL8738231 | 0.75 | DRD2 (0.77) | MCHR1SLC2A1 | |
| SCHEMBL8738579 | 0.75 | DRD2 (0.77) | MCHR1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | claimed |
| EP-1904446-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | claimed |
| WO-2007007282-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | claimed |
| US-20090012116-A1 | Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| EP-1904446-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007007282-A2 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012116-A1 | Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | MCHR2 85/4885MCHR1 71/4885CHRM4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.